MDGL - Madrigal Pharmaceuticals, Inc.
| Previous Close | 103.54 |
| Open | 103.23 |
| Bid | 93.05 x 900 |
| Ask | 115.99 x 1000 |
| Day's Range | 96.54 - 103.23 |
| 52 Week Range | 89.83 - 315.00 |
| Volume | 202,633 |
| Avg. Volume | 191,546 |
| Market Cap | 1.504B |
| Beta (3Y Monthly) | 1.82 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.75 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 212.36 |
GuruFocus.com•10 days ago2 Falling Knives With No Debt
Warning! GuruFocus has detected 3 Warning Signs with IRDM. The risk is very high with this kind of investment, but if investors look for companies that have no debt and a moderate to high current ratio, the risk can be significantly decreased. In addition, the companies have received an overweight recommendation rating from Wall Street, increasing the chances of a successful bet as these stocks are expected to outperform their industries within 12 months.
- GlobeNewswire•13 days ago
Madrigal Pharmaceuticals to Present at Upcoming Investment Conferences
CONSHOHOCKEN, Pa., June 04, 2019 -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced that Paul Friedman, M.D., Chief Executive Officer of Madrigal, and Becky Taub,.
- GlobeNewswire•last month
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by the Certain Officers and Directors of Madrigal Pharmaceuticals, Inc.
NEW YORK, May 15, 2019 -- Levi & Korsinsky announces it has commenced an investigation of Madrigal Pharmaceuticals, Inc. (NASDAQCM: MDGL) concerning possible breaches of.
- Simply Wall St.•last month
If You Had Bought Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock A Year Ago, You'd Be Sitting On A 12% Loss, Today
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! The simplest way to benefit from a rising market is to buy an index fund. But if you buy individ...
- Associated Press•last month
Madrigal: 1Q Earnings Snapshot
On a per-share basis, the West Conshohocken, Pennsylvania-based company said it had a loss of 98 cents. The results missed Wall Street expectations. The average estimate of six analysts surveyed by Zacks ...
- GlobeNewswire•last month
Madrigal Pharmaceuticals Reports 2019 First Quarter Financial Results and Highlights
CONSHOHOCKEN, Pa., May 08, 2019 -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced its first quarter 2019 financial results and highlights: “Madrigal continued to.
- Insider Monkey•2 months ago
Is Madrigal Pharmaceuticals, Inc. (MDGL) A Good Stock To Buy?
Many investors, including Paul Tudor Jones or Stan Druckenmiller, have been saying before the Q4 market crash that the stock market is overvalued due to a low interest rate environment that leads to companies swapping their equity for debt and focusing mostly on short-term performance such as beating the quarterly earnings estimates. In the fourth […]
- GlobeNewswire•2 months ago
Madrigal Pharmaceuticals to Present Additional Analyses of Data from The Phase 2 NASH Study with MGL-3196 (resmetirom) at The International Liver Congress™ 2019
-- MRI-PDFF response (≥30% reduction in hepatic fat) at 12 weeks correlated with reduction in the ballooning and inflammation components of NAS and was predictive of NASH.
- Motley Fool•2 months ago
Here's Why Investors Are Betting Against These 2 Biotech Stocks
Are intrepid short-sellers taking advantage of misguided enthusiasm?
- GlobeNewswire•3 months ago
Madrigal Pharmaceuticals Initiates Phase 3, Multinational, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 (resmetirom) in Patients With Non-Alcoholic Steatohepatitis (NASH) and Fibrosis to Resolve NASH and Reduce Progression to Cirrhosis and/or Hepatic Decompensation
Madrigal Pharmaceuticals, Inc. (MDGL) announced today that it has initiated its Phase 3 trial in NASH with its once daily, oral thyroid hormone receptor beta selective agonist, MGL-3196 (resmetirom). This double-blind, placebo-controlled study will be conducted at more than 150 sites in the United States and the rest of the world.
- Zacks•4 months ago
Intercept (ICPT) Up on Q4 Revenue Beat, NASH Study in Focus
Intercept's (ICPT) Q4 revenues top estimates owing to strong Ocaliva sales, driven by sales force expansion and growth in its foreign geographies.
- Motley Fool•4 months ago
Is Viking Therapeutics a Buy?
Once sky-high stocks of pharmaceutical companies pursing treatments for NASH have gotten a lot cheaper, especially this one.
- Simply Wall St.•4 months ago
All You Need To Know About Madrigal Pharmaceuticals, Inc.’s (NASDAQ:MDGL) Financial Health
Mid-caps stocks, like Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) with a market capitalization of US$2.1b, aren’t the focus of most investors who prefer to direct their investments towards either large-cap or small-capRead More...
- GlobeNewswire•4 months ago
Madrigal Pharmaceuticals Reports 2018 Fourth Quarter and Full Year Financial Results and Highlights
CONSHOHOCKEN, Pa., Feb. 27, 2019 -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced its fourth quarter and full year 2018 financial results and highlights:.
- Zacks•4 months ago
Intercept Reports Positive Top-Line Data for NASH, Shares Up
Intercept (ICPT) reports positive top-line results from its pivotal phase III REGENERATE study of OCA in patients with liver fibrosis due to NASH.
- Motley Fool•4 months ago
Better Buy: Intercept Pharmaceuticals vs. Madrigal Pharmaceuticals
Which of these NASH stocks is the better pick right now?
- Zacks•4 months ago
Gilead's (GILD) Late-Stage Study on Liver Disease Drug Fails
Gilead (GILD) suffers a setback as its phase III study on pipeline candidate, selonsertib, in patients with compensated cirrhosis (F4) due to NASH fails to meet goal.
- Motley Fool•5 months ago
Here's Why Viking Therapeutics Slid 32.2% in December
A market scorned for clinical-stage biotech stocks tore a big chunk from this NASH drug developer.
- Motley Fool•5 months ago
Here's Why Viking Therapeutics Skyrocketed 88.4% in 2018
The clinical-stage biotech hopes to tap into what could be a megablockbuster indication.
- Zacks•6 months ago
Intercept (ICPT) Benefits from Ocaliva's Recovery in 2018
Intercept (ICPT) outperforms the broader market in 2018 as lead drug Ocaliva recovers, following the company's efforts to increase awareness about the updated label.
- Insider Monkey•6 months ago
Here is What Hedge Funds Think About Madrigal Pharmaceuticals, Inc. (MDGL)
Looking for stocks with high upside potential? Just follow the big players within the hedge fund industry. Why should you do so? Let’s take a brief look at what statistics have to say about hedge funds’ stock picking abilities to illustrate. The Standard and Poor’s 500 Index returned approximately 5.7% in the 12 months ending October 26 […]
- Motley Fool•6 months ago
3 Beaten-Down Biotech Stocks That Could Bounce Back in 2019
A new year and reasons to remain hopeful for these three biotechs are around the corner.
- Motley Fool•6 months ago
Here's Why Madrigal Pharmaceuticals Fell 39.4% in November
Impressive results from a potential competitor took the shine off this biotech's experimental NASH treatment.
- GlobeNewswire•7 months ago
Report: Exploring Fundamental Drivers Behind CASI Pharmaceuticals, Booking, Enstar Group, Madrigal Pharmaceuticals, Dermira, and Kaiser Aluminum — New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, Nov. 28, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- GuruFocus.com•7 months ago
Madrigal Pharmaceuticals Inc (MDGL) CEO Paul A Friedman Bought $471,520 of Shares
Madrigal Pharmaceuticals Inc is a company focused on the development of novel compounds for the treatment of cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH). Madrigal Pharmaceuticals Inc had annual average EBITDA growth of 43.80% over the past five years. Warning! GuruFocus has detected 4 Warning Signs with T. Click here to check it out.
